The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...
Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccinewas cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around Robert ...
Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
(Reuters) -Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human ...
Investor's Business Daily on MSN14h
Is Moderna Stock A Buy As Its CEO Fends Off RFK Jr. Concerns?Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...
Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback